经新辅助或转化治疗术后分期为ypT0~1NanyM0局部进展期胃癌54例预后分析

目的 分析经新辅助或转化治疗术后分期为ypT0~1NanyM0的局部进展期胃癌病人的长期预后。方法 回顾性分析2008年1月至2020年1月中国人民解放军东部战区总医院普外科收治的经新辅助或转化治疗后行根治性切除手术，且术后分期为ypT0~1NanyM0的54例局部进展期胃癌病人的临床资料，应用Kaplan-Meier法计算病人3年和5年的总体生存率及无进展生存率，并比较术后分期为ypT0N0M0与ypT1N0M0病人之间的生存差异。结果 共纳入54例局部进展期胃癌病人。10例（18.5%）病人术前接受常规给药途径的SOX化疗方案，44例采用动静脉结合的化疗方法，其中31例（57.4%）为SEEOX方案，13例（24.1%）为FLEEOX方案。所有病人均实施D2或D2+淋巴结清扫，并获得R0切除。30例（55.6%）病人行全胃切除术，24例（44.4%）行远端胃切除术。术后分期为ypT0N0M0病人38例（70.4%），ypT1N0M0病人11例（20.4%）。所有病人术后均接受辅助化疗。随访56.5（13.1～170.3）个月，共有15例病人死亡，其中11例病人因肿瘤局部复发或远处转移死亡，复发转移时间为18.9（7.8～55.5）个月。3年和5年总体生存率分别为83.2%和76.4%，3年和5年无进展生存率分别为83.1%和72.8%。分期为ypT0N0M0与ypT1N0M0病人生存时间比较结果显示，总体生存时间［中位生存时间为尚未达到（NR） vs. 5.2年，HR=0.46，95%CI 0.12-1.68，P=0.138］和无进展生存时间（NR vs 4.6年，HR=0.57，95%CI 0.15-2.20，P=0.337）差异均无统计学意义。结论 经新辅助或转化治疗术后分期为ypT0~1NanyM0 的局部进展期胃癌病人长期预后较好，且ypT1N0M0与ypT0N0M0病人的长期生存时间相近。     

Liposarcoma of the Great Toe: A Case Report

Soft tissue sarcomas are rare malignancies, of which liposarcomas are the most common. Pleomorphic liposarcoma accounts for 5% of liposarcoma diagnoses and most commonly presents in the thigh. A 57-year-old female presented with a 5-year history of a persistent, painless swelling of the left great toe that had been previously diagnosed and treated as an in-grown toenail. After magnetic resonance imaging and core biopsy, a grade 2 pleomorphic liposarcoma was diagnosed. Treatment consisted of neoadjuvant radiotherapy and amputation of the great toe and proximal half of the first metatarsal with primary closure. The patient had no evidence of local recurrence or metastatic disease after 1 year of follow-up and, with the use of a prosthesis, had a good functional outcome. This is the first documented presentation of a high-grade pleomorphic liposarcoma of the great toe to our knowledge. Although soft tissue sarcomas are rare, a high index of suspicion is required by clinicians when presented with a soft tissue mass to promptly diagnose and treat these potentially fatal lesions.     

Extracapsular extension in oral cavity cancers—predictive factors and impact on recurrence pattern and survival

Extracapsular extension (ECE) has long been considered a poor prognostic factor in oral cavity cancer, the presence of which warrants intensification of adjuvant therapy. This study was done to analyze the survival of patients with ECE who received adjuvant chemoradiation. Patients with pathologically confirmed squamous cell carcinoma of the oral cavity, with a minimum of 2 years of follow-up, who were treated at a tertiary cancer centre in New Delhi, India during the years 2009–2017, were included. On multivariate analysis, ECE was significantly associated with depth of invasion >10 mm and tumour deposit size >5 mm. Among the node-positive group, patients without ECE had a 5-year disease-free survival (DFS) and 5-year overall survival (OS) advantage over ECE-positive patients of 7.8% (63.8% vs. 56.0%) and 16.5% (87.2% vs. 70.7%), respectively. For patients with ECE, the hazard ratio for DFS and OS was 1.3 (95% confidence interval 0.97–1.75, P = 0.078) and 2.30 (95% confidence interval 1.35–3.92, P = 0.002), respectively. ECE remains one of the strongest predictors of recurrence and survival in oral cancer patients, and despite aggressive adjuvant therapy, distant recurrence is still significantly high.     

Can patients with head and neck cancers invading carotid artery gain survival benefit from surgery?

Conclusion. Surgical treatment of carotid invasion may give an improved 2-year survival in selected patients without significant morbidity. Objective. To evaluate survival outcomes in patients with head and neck squamous cell carcinomas invading the carotid artery. Patients and methods. At the time of carotid invasion, 23 patients underwent surgery (n=11), chemoradiotherapy (n=6), or palliation (n=6). Surgical methods included carotid resection and ligation (n=5), carotid resection and reconstruction with saphenous vein (n=4), and peeling (n=2). Survival outcomes among different treatments were compared. Results. None of the 11 surgical patients experienced perioperative mortality or major neurologic complications. Three of these patients survived, but two had recurrent disease at last follow-up; their 2-year overall survival and disease-free survival rates were 24.5% and 18.2%, respectively. In contrast, all patients treated with chemoradiation or palliation died within 15 months. Median survival time was 16.5 months in the surgery group, 11.5 months in the chemoradiation group, and 3 months in the palliation group (p=0.025).